Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes: To the editor

New England Journal of Medicine

Volumn 374, Issue 11, 2016, Pages 1093-1094

  Rosenstein, Robert ^a   Hough, Augustus ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

CARDIOVASCULAR DISEASE; DIABETIC KETOACIDOSIS; DRUG SAFETY; DRUG USE; FOOD AND DRUG ADMINISTRATION; HUMAN; LETTER; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK; TREATMENT OUTCOME; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; MALE;

BENZHYDRYL COMPOUNDS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; MALE;

EID: 84961783251     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1600827     Document Type: Letter

References (1)

1. Department of Health and Human Services, Food and Drug Administration. FDA Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. May 15, 2015 (http://www .fda .gov/downloads/Drugs/DrugSafety/UCM446954 .pdf).